Sunday, September 25, 2022 11:09:50 PM
6,098,203 Existing shareholders prior to IPO
1,282,600 New shares sold with IPO
7,380,803 Total as of June 30, 2022
Issuance Details: (there is a difference of 270,629 more than what's stated above)
2,570,650 shares of Common Stock issuable upon the exercise of the Warrants underlying the Units sold in this Offering;
192,390 shares of Common Stock issuable upon the exercise of the Over-Allotment Option
192,390 shares of Common Stock issuable upon the exercise of 192,390 Tradeable Warrants issuable upon the exercise of the Over-Allotment Option
192,390 shares of Common Stock issuable upon the exercise of 192,390 Non-tradeable Warrants issuable upon the exercise of the Over-Allotment Option
25,562 shares of Common Stock issuable upon the exercise of the Representative’s Warrant and 29,464 shares of Common Stock issuable upon the exercise of the Placement Agent’s Warrant
756,558 shares of Common stock issuable upon the conversion of Series A Preferred ?Stock
871,240 shares of ?Common Stock issuable on the exercise of stock options; and
2,850,252 shares of Common Stock issuable on the exercise of outstanding warrants issued to the holders of our convertible notes with a weighted average exercise price equal to $5.25 per share.
Recent BIAF News
- bioAffinity Technologies Reports Record Q1 Revenue Driven by Accelerating Growth of CyPath® Lung Sales and Increased Laboratory Volumes • Business Wire • 05/15/2024 01:15:00 PM
- bioAffinity Technologies News Update • Business Wire • 05/02/2024 12:00:00 PM
- bioAffinity Technologies Advances New Product Development Initiatives to Accelerate Next Phase of Growth • Business Wire • 04/24/2024 12:00:00 PM
- bioAffinity Technologies Expands Campaign to Support American Cancer Society Initiative for Lung Cancer Screening • Business Wire • 04/09/2024 12:00:00 PM
- bioAffinity Technologies Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 04/01/2024 01:49:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 10:00:45 PM
- Wallachbeth Capital Announces Closing of bioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement • PR Newswire (US) • 03/08/2024 06:15:00 PM
- bioAffinity Technologies Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement • Business Wire • 03/08/2024 05:45:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/08/2024 05:18:40 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/08/2024 02:57:51 AM
- WallachBeth Capital Announces Pricing of BioAffinity Technologies $2.5 Million Registered Direct Offering and Concurrent Private Placement • PR Newswire (US) • 03/06/2024 03:45:00 PM
- bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement • Business Wire • 03/06/2024 02:46:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 10:26:46 PM
- bioAffinity Technologies Reports Accelerating Sales Growth of CyPath® Lung • Business Wire • 03/05/2024 01:00:00 PM
- bioAffinity Technologies News Update • Business Wire • 02/21/2024 01:00:00 PM
- Medical Director of Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice • Business Wire • 02/06/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:25:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:22:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:21:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:17:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 09:05:25 PM
- bioAffinity Technologies In The News • Business Wire • 01/30/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 01:52:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 01:52:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 01:52:34 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM